Firefly Neuroscience, Inc. is an artificial intelligence (AI) technology company developing neuroscientific solutions to improve brain health outcomes for patients with mental illnesses and neurological disorders. The Company has developed its FDA-510(k) cleared Brain Network Analytics software platform (the BNA Platform) and is focused on advancing diagnostic and treatment approaches for people suffering from mental illnesses and cognitive disorders, including depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder. The Company's Brain Network Analytics is a neurophysiological assessment tool that uses artificial intelligence and machine learning to analyze electroencephalogram (EEG) data recorded during rest and cognitive activity. The BNA Platform, in conjunction with an EEG system, provides clinicians with comprehensive insights into brain function (cognition).
Growing
The company is in a growing phase, with the latest annual income totaling USD 1.14M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 1.14M.
Undervalued
The company’s latest PE is -3.59, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 1.05M shares, decreasing 41.27% quarter-over-quarter.